Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Ovarian Carcinoma
100%
Endothelial Cells
100%
STI571
100%
Multi-target
100%
AEE788
100%
Pericytes
100%
Antivascular Therapy
100%
Tumor Growth
60%
Paclitaxel
60%
Pericyte Coverage
60%
Tumor
40%
Treatment Group
40%
Microvessel Density
40%
Endothelial Cell Apoptosis
40%
Inhibition Rate
40%
Triple Combination
40%
Improved Survival
20%
Survival Benefit
20%
Additional Therapy
20%
Clinical Trials
20%
Antiangiogenic Activity
20%
Therapeutic Efficacy
20%
Highly Effective
20%
Vascular Endothelial Growth Factor Receptor Inhibitor
20%
Tumor Endothelial Cells
20%
Tumor Vasculature
20%
In Vivo Applications
20%
Group Density
20%
Survival Study
20%
Induced Endothelial Cells
20%
Orthotopic Tumor
20%
Paclitaxel Resistance
20%
Medicine and Dentistry
Krukenberg Tumor
100%
Endothelial Cell
100%
Pericyte
100%
Imatinib
62%
6 [4 (4 Ethyl 1 Piperazinylmethyl)phenyl] 4 (Alpha Methylbenzylamino) 7h pyrrolo[2,3 D]pyrimidine
62%
Paclitaxel
50%
Tumor Progression
37%
Programmed Cell Death
25%
Microvessel
25%
Treatment Group
25%
Tumor
25%
Neoplasm
12%
Clinical Trial
12%
Cancer Therapy
12%
Vasculotropin Receptor
12%
Antiangiogenic Activity
12%
Tumor Vascularization
12%
Pharmacology, Toxicology and Pharmaceutical Science
Imatinib
100%
Ovary Carcinoma
100%
6 [4 (4 Ethyl 1 Piperazinylmethyl)phenyl] 4 (Alpha Methylbenzylamino) 7h pyrrolo[2,3 D]pyrimidine
100%
Paclitaxel
80%
Tumor Growth
60%
Treatment Group
40%
Vasculotropin Receptor
20%
Neoplasm
20%
Clinical Trial
20%
Antiangiogenic
20%
Tumor Vascularization
20%